갑상선암 표적치료의 최신지견

• 영문명: What s New in Molecular Targeted Therapies for Thyroid Cancer?
• 발행기관: 대한두경부종양학회
• 저자명: 민선영(Seonyoung Min) 강현석(Hyunseok Kang)
• 간행물 정보: 『대한두경부종양학회지』제37권 제2호, 1~9쪽, 전체 9쪽
• 주제분류: 의약학 > 종양학
• 파일형태: PDF
• 발행일자: 2021.11.30

영문 초록

Thyroid cancer refers to various cancers arising from thyroid gland. Differentiated thyroid cancers (DTCs) in-clude papillary, follicular, and Hurthle cell carcinomas and represent cancers retain normal thyroid functions such as iodine uptake. Radioactive iodine (RAI) is generally used for upfront treatment of metastatic DTCs, but RAI refractory DTCs remain to be clinical challenges. Sorafenib and lenvatinib were approved for the treatment of RAI refractory DTCs and more recently, genomics-based targeted therapies have been developed for NTRK and RET gene fusion-positive DTCs. Poorly differentiated and anaplastic thyroid cancers (ATCs) are extremely challenging diseases with aggressive courses. BRAF/MEK inhibition has been proven to be highly effective in BRAF V600E mutation-positive ATCs and immune checkpoint inhibitors have shown promising activities. Medullary thyroid cancers, which arise from parafollicular cells of thyroid, represent a unique subset of thyroid cancer and mainly driven by RET mutation. In addition to vandetanib and cabozantinib, highly specific RET inhibitors such as selpercatinib and pralsetinib have demonstrated impressive activity and are in clinical use.

목차

Introduction

Biology of thyroid cancers

Established targeted therapy for thyroid cancers

Emerging therapy for thyroid cancers

Conclusion

References

키워드

Thyroid cancer Targeted therapy Precision Oncology Genomics-driven systemic therapy